Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MannKind Corporation (MNKD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into MannKind’s operations as a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Among the key filings are Form 8-K current reports, which MannKind uses to describe material events. Recent 8-Ks document the completion of the acquisition of scPharmaceuticals, the terms of the related Contingent Value Rights Agreement, and the creation of additional borrowing capacity under a loan agreement to finance the transaction. Other 8-K filings discuss quarterly financial results, including revenue contributions from Afrezza, FUROSCIX, V-Go, and Tyvaso DPI–related royalties and collaborations, as well as changes in research and development and selling, general and administrative expenses.
Filings also cover MannKind’s clinical and regulatory decisions. For example, an 8-K filed in November 2025 describes the discontinuation of the Phase 3 ICoN-1 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease following a futility determination, and outlines the company’s intention to use those findings to guide ongoing development of MNKD-102, a dry powder formulation of clofazimine. Another 8-K details the first amendment to the global license and collaboration agreement with United Therapeutics, under which MannKind will formulate an additional Technosphere-based investigational product and is eligible for development milestones and royalties.
On this page, investors can review MannKind’s SEC-reported information on mergers and acquisitions, collaboration agreements, financing arrangements, and clinical program updates. Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand transaction structures, milestone obligations, and the potential impact on MannKind’s business. Users can also monitor newly posted 8-Ks and other SEC forms in near real time as they are released on EDGAR.
MannKind Corporation reported an insider stock sale by Chief People & Workplace Officer Stuart A. Tross. On January 8, 2026, he sold 47,006 shares of MannKind common stock at a price of $6.33 per share. After this transaction, he continued to beneficially own 985,007 shares of common stock in direct ownership form. The filing notes that the sale occurred pursuant to a pre-established Rule 10b5-1 trading plan that was put in place on June 17, 2025, indicating the trades were scheduled in advance.
A Rule 144 notice reports a planned sale of 47,000 common shares of the issuer through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an aggregate market value of $297,510.00 and an approximate sale date of 01/08/2026. The filing states that 307,070,281 shares of this class were outstanding.
The shares to be sold were acquired as performance shares from the issuer, including 24,636 shares acquired on 05/22/2023 and 22,364 shares acquired on 05/17/2024, both listed as having payment noted as not applicable.
MannKind Corp Chief Executive Officer and director Michael Castagna reported stock option exercises and related share sales in recent insider transactions. On 12/12/2025 he exercised 20,806 employee stock options at $4.55 per share and sold 20,806 shares of common stock at $6, leaving him with 2,504,792 common shares held directly. On 12/16/2025 he exercised a further 21,310 options at $4.55 and sold 21,310 common shares at $6, again ending with 2,504,792 directly held shares. Following these trades, he beneficially owns 15,804 employee stock options with a $4.55 exercise price expiring on 05/19/2026. The transactions were carried out under a Rule 10b5-1 trading plan established on August 8, 2025.
MannKind Corporation filed Amendment No. 1 to a prior current report related to its completed merger with scPharmaceuticals Inc. The update focuses on providing fuller financial information for the acquired business and the combined company.
The amendment adds audited consolidated financial statements of scPharma for the year ended December 31, 2024, unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2025, and unaudited pro forma condensed combined financial information for MannKind for the six months ended June 30, 2025 and the year ended December 31, 2024. It also lists related exhibits, including the merger agreement, a contingent value rights agreement, a loan agreement amendment, and the auditor’s consent, while leaving all other parts of the original report unchanged.
MannKind Corporation executive reports stock sale under pre-set plan. On 11/14/2025, an officer of MannKind Corp (MNKD), serving as EVP Technical Operations, sold 18,777 shares of common stock in an open-market transaction coded as a sale. The weighted average sale price was $5.03 per share, based on individual trades between $5.00 and $5.07. After this transaction, the executive directly beneficially owned 455,211 shares of MannKind common stock. The filing notes that the sale occurred pursuant to a Rule 10b5-1 trading plan that was established on May 14, 2025, indicating the trades were made according to a pre-arranged schedule.
MannKind (MNKD) filed a Form 4 showing its Chief Medical Officer acquired 318,200 shares of common stock via restricted stock units on 11/11/2025 at a price of $0. Following the grant, the reporting person beneficially owned 318,200 shares, held directly.
The RSUs carry a four-year vesting schedule: no shares vest on the first anniversary of the vesting determination date of September 29, 2025, and one-third vests on each anniversary thereafter until fully vested on the fourth anniversary.
MannKind Corporation is discontinuing its Phase 3 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease after an interim analysis for the first 46 participants who completed the double-blind phase showed no sputum culture conversions, indicating futility.
The data safety monitoring board reviewed the results on November 8, 2025 and agreed with stopping the study; no safety issues were identified. MannKind plans to investigate the outcome and apply learnings to MNKD-102, a dry powder clofazimine formulation progressing from pre-clinical toward Phase 1.
MannKind Corporation reported Q3 2025 results with total revenue of
Revenue mix: product revenue
On the balance sheet, cash and cash equivalents were
MannKind Corporation furnished a current report to announce that it issued a press release addressing results of operations and financial condition. The press release is included as Exhibit 99.1. This administrative update signals that the company has released its latest performance communication, with full details contained in the accompanying press release.
MannKind Corp (MNKD) reported an insider Form 4 for its EVP of Technical Operations. On 10/31/2025, the company withheld 17,071 shares of common stock in a transaction coded F, reflecting shares retained by the issuer to cover taxes upon vesting of previously reported RSUs at a price of $5.59 per share.
Following this tax-withholding event, the reporting person directly beneficially owns 473,988 shares of MannKind common stock.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
